Navigation Links
Medications can help adults with alcohol use disorders reduce drinking
Date:5/13/2014

Several medications can help people with alcohol use disorders maintain abstinence or reduce drinking, according to research from the University of North Carolina at Chapel Hill.

The work, published today in the Journal of the American Medical Association (JAMA) and funded by the Agency for Healthcare Research and Quality (AHRQ), provides additional options for clinicians to effectively address this global concern.

Although alcohol use disorders are associated with many health problems, including cancers, stroke and depression, fewer than one-third of people with the disorders receive any treatment and less than 10 percent receive medications to help reduce alcohol consumption.

"There are many studies that have tried to show whether certain medications can help with alcohol use disorders, but it is a lot of information to digest and many providers do not know what works or doesn't work," said Daniel Jonas, lead author of the study and professor in the department of medicine and the Cecil G. Sheps Center for Health Services Research. "When you synthesize all the evidence, it shows pretty clearly that some medications do work."

Jonas led a team from the RTI-UNC Evidence-based Practice Center to review published studies examining the use of drugs to treat alcohol use disorders. The researchers conducted a systematic review of 122 randomized controlled trials and one cohort study. They then graded the strength of the evidence on the impact of drugs on alcohol consumption.

They found that two drugs, acamprosate (brand name Campral) and oral naltrexone (brand name Revia), have the best evidence supporting their benefits. Both drugs reduced return to drinking and improved other drinking outcomes. Among medications used off-label (i.e., those not FDA approved for alcohol use disorders), moderate evidence showed improvement in some drinking outcomes for topiramate and nalmefene.

"The health implications of preventing return to drinking and reducing alcohol consumption are substantial," said Jonas. "Modeling studies have shown that such improvements would result in significant reductions in alcohol-attributable mortality, costs from health care, arrests and motor vehicle accidents."

"This work expands upon the growing evidence that medications can play a valuable role in the treatment of alcohol use disorders," said James Garbutt, professor of psychiatry and scientist at UNC's Bowles Center for Alcohol Studies and senior author on the paper. "We are hopeful that this information will encourage clinicians to strongly consider these medications and that individuals will gain awareness that there are medications that can help them to stop or significantly reduce their alcohol use."

The study was developed by the AHRQ-funded RTI-UNC Evidence-based Practice Center is a collaboration between RTI International and the University of North Carolina at Chapel Hill. Jonas co-directs the center with Meera Viswanathan at RTI. The review is an update of the first product of the center, which was published in 1999 in JAMA. Since 1999, there has been more than a tenfold increase in the number of individuals studied in controlled clinical trials of naltrexone and acamprosate, and many trials of medications that are not FDA-approved.


'/>"/>

Contact: Thania Benios
thania_benios@unc.edu
919-962-8596
University of North Carolina at Chapel Hill
Source:Eurekalert

Related medicine news :

1. Nearly 50 percent of M.D.s believe diversion of ADHD stimulant medications among teens is a problem
2. UH Rainbow to study African-Americans response to asthma medications
3. HHS leaders call for expanded use of medications to combat opioid overdose epidemic
4. One in 5 older Americans take medications that work against each other
5. Anti-psychotic medications offer new hope in the battle against glioblastoma
6. Blood pressure medications given right after stroke not beneficial, study finds
7. MIT robot may accelerate trials for stroke medications
8. Fresno California's Hear for Life Hearing Aid Centers Publishes Warnings about Medications that Lead to Hearing Loss
9. Audiologists at American Hearing & Balance in Marina del Rey CA Educate Consumers About Everyday Medications That Cause Hearing Loss
10. Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for Individuals Allegedly Injured by Recalled Dialysis Medications
11. Effect of reducing blood pressure with medications immediately following ischemic stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... Project has named LaToya Williams-Belfort to the position of Chief Development and Communications Officer. ... nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors to ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and in ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, and therefore life ... advantaged communities providing richer opportunities. Recognizing the key role of housing in this ... (b) school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) ...
(Date:5/24/2016)... ... May 24, 2016 , ... New Brunswick, New Jersey: This year marks ... reach their fullest potential. To commemorate the anniversary, the hospital has themed the milestone ... Roll for Children’s Specialized Hospital Foundation on Saturday, May 21, at Johnson Park in ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- ... of its Advisory Board. Joining the Grow Healthy Advisory Board ... of them embody the mission of our organization and bring talent, ... have them as we continue to expand our footprint as the ...
(Date:5/24/2016)... Fla. (PRWEB) , ... May 24, 2016 , ... Boyd ... the Concealed Delivery Unit® (CDU), a groundbreaking new product for pediatric dentistry , ... Pediatric Dentistry in San Antonio, TX May 26-29. The Concealed Delivery Unit keeps dental ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... HONG KONG , May 24, 2016 /PRNewswire/ ... primer stent de doble terapia del mundo, introduce ... fístula arteriovenosa. OrbusNeich, una compañía global ... cambian las vidas, ha expandido su cartera incluyendo ... catéteres balón JADE™ y Scoreflex™ PTA son los ...
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... Transparency Market Research has published ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... report, the exocrine pancreatic insufficiency market is anticipated to ... 2023 to reach US$2.85 Bn by 2023. ... the deficiency of the exocrine pancreatic enzymes, causing failure ...
Breaking Medicine Technology: